Form 4: Mineralys Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Daphne Karydas, a Director of Mineralys Therapeutics, Inc., sold 3,000 shares of common stock on September 15, 2026 for $28.58 per share.
Summary
- Option exercise/conversion: acquired 3,000 Common Stock at $12.02 ($36,060) on September 15, 2026; holds 9,200 after (Direct).
- Open-market sale: disposed of 3,000 Common Stock at $28.58 ($85,740) on September 15, 2026; holds 6,200 after (Direct).
- Option exercise/conversion: disposed of 3,000 Stock Option on September 15, 2026; holds 35,000 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $85,740 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Daphne Karydas — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Option exercise/conversion | Common Stock | 3,000 | $12 | $36.1K | 9,200 |
| 2026-09-15 | Open-market sale | Common Stock | 3,000 | $29 | $85.7K | 6,200 |
| 2026-09-15 | Option exercise/conversion | Stock Option | 3,000 | — | — | 35,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Option exercise/conversion (3,000 shares) |
| 2026-09-15 | Open-market sale (3,000 shares) |
| 2026-09-15 | Option exercise/conversion (3,000 shares) |
Keywords
insider transaction, Form 4, MLYS, Mineralys Therapeutics, Inc., bearish, Daphne Karydas
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.